CELC: Launch access is advancing as the mutant-setting PDUFA and clinical catalysts approach
Celcuity Inc. (CELC) has seen its REVTORPYK launch reach 78% of top strategic accounts in its first month, with positive early feedback on tolerability. The company anticipates key catalysts including a mutant-setting PDUFA in Q2 2027, further clinical data releases, and ongoing sales updates. This information is based on an audio transcript from the Jefferies Global Healthcare Conference on November 18, 2026.
CELC: Launch access is building as phase III and first-line opportunities expand
Celcuity Inc. (CELC) is demonstrating strong early launch access metrics, bolstered by positive Phase III results and first-line data that indicate broad market opportunities. The company has several key milestones on the horizon, including a mutant sNDA review, completion of prostate Phase II trials in 2027, and an expansion of its manufacturing capacity. This information is based on an AI-generated summary of Celcuity Inc.'s Stifel 2026 Healthcare Conference audio transcript from November 11, 2026.
Celcuity at guggenheim healthcare innovation conference: launch gains pace By Investing.com
Celcuity announced at the 3rd Annual Guggenheim Healthcare Innovation Conference that its newly launched cancer drug, REVTORPYK, is gaining early traction, with 80% of strategic accounts now ordering it. The company highlighted broad payer coverage and provider pathway inclusion in top health systems, along with a robust pipeline in breast and prostate cancer. Despite an initial stock dip, Celcuity is prioritizing growth opportunities over near-term profitability, backed by analyst price targets suggesting significant upside.
FDA accepts Celcuity application for expanded breast cancer use
Celcuity Inc. announced that the FDA has accepted its supplemental New Drug Application for REVTORPYK to treat patients with hormone receptor positive, HER2 negative, locally advanced or metastatic breast cancer with a PIK3CA mutation. The FDA set a Prescription Drug User Fee Act goal date of June 25, 2027, for this application, which is based on data from the Phase 3 VIKTORIA-1 clinical trial. REVTORPYK had previously received Breakthrough Therapy and Fast Track designations and was already approved for similar breast cancer patients without a PIK3CA mutation.
Is Celcuity (CELC) Undervalued After Its Q3 Loss Raised Fresh Questions?
Celcuity (CELC) reported a wider net loss and higher basic loss per share in Q3 2026, leading to a recent stock price decline despite a slight bounce after earnings. Analysts still consider the stock 56% undervalued with a fair value of $152.72, supported by recent financing that provides funding through 2027. However, the company faces risks related to heavy R&D spending, ongoing net losses, and clinical uncertainties surrounding its drug candidate, gedatolisib.
HC Wainwright & Co. maintains Celcuity at Buy, lowers price target to $150 from $155
HC Wainwright & Co. has maintained its "Buy" rating for Celcuity but slightly lowered its price target from $155 to $150, representing a 3.2% decrease. This new price target implies a significant upside of 124.6% from the stock's closing price on November 6. Recent analyst actions from Guggenheim, Cantor Fitzgerald, and TD Cowen show price targets for Celcuity ranging from $140 to $169.
Celcuity Announces FDA Acceptance of sNDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
Celcuity Inc. announced that the FDA has accepted its supplemental New Drug Application (sNDA) for REVTORPYK™ (gedatolisib) to treat HR+/HER2-, PIK3CA mutant locally advanced or metastatic breast cancer. The FDA has assigned a PDUFA goal date of June 25, 2027, for this submission, which is based on data from the Phase 3 VIKTORIA-1 clinical trial. If approved, REVTORPYK would be available as a second-line therapy for a broader patient population, regardless of PIK3CA status.
Celcuity Announces FDA Acceptance of sNDA for REVTORPYK™
Celcuity Inc. announced that the FDA has accepted its supplemental New Drug Application (sNDA) for REVTORPYK™ (gedatolisib) for the treatment of HR+/HER2-, PIK3CA mutant locally advanced or metastatic breast cancer. The FDA has set a PDUFA goal date of June 25, 2027. This submission is based on data from the Phase 3 VIKTORIA-1 clinical trial, aiming to expand REVTORPYK's availability to a broader patient population.
Plans serving 91% of people with commercial or Medicare insurance cover a new breast cancer drug.
Celcuity (Nasdaq: CELC) reported a Q3 net loss of $73.3 million, widening from $43.8 million a year prior, as it commenced commercialization of its new breast cancer drug, REVTORPYK, which became available on September 30, 2026. Despite no product revenue in the quarter, the drug has secured coverage with health plans representing 91% of U.S. commercial and Medicare lives, with 78% of top strategic accounts placing orders. The company also submitted an application for an additional indication for PIK3CA-mutant breast cancer and expects current cash resources to fund operations through 2029.
How Investors Are Reacting To Celcuity (CELC) Wider Loss And Trial Data
Celcuity (CELC) reported a wider net loss for Q3 2026 of US$73.34 million, alongside updated clinical results for gedatolisib in advanced breast and prostate cancer which suggest progression-free survival benefits. Analysts project a sharp swing to profitability for Celcuity by 2029, with revenue reaching US$945.0 million and earnings of US$230.6 million, though some cautious estimates reflect greater financing risk. The article emphasizes that despite the promising trial data, significant risks remain regarding regulatory approval, market uptake, and the company's dependency on its single lead asset.
Celcuity Q3 2026 Earnings Call Transcript
Celcuity (NASDAQ: CELC) reported a Q3 2026 net loss of $73.3 million, with no revenue due to the timing of Retropic shipments, their newly launched drug for HR-positive, HER2-negative breast cancer. Despite the lack of immediate revenue, the company achieved strong early adoption with 78% of top strategic accounts ordering Retropic and secured broad payer coverage. Celcuity also provided positive clinical updates for Retropic and an update on its prostate cancer program, expressing optimism about future growth and financial stability through 2029 due to a recent convertible note offering.
With no Q3 product revenue, Celcuity (CELC) reports a wider net loss.
Celcuity Inc. reported a wider net loss of $73.3 million for Q3 2026 and $205.0 million for the nine months ended September 30, 2026, compared to previous periods. Despite FDA approval of REVTORPYK and the start of shipments on September 30, 2026, no product revenue was recognized for the quarter as healthcare providers and pharmacies had not received the product by quarter-end. The company continues to invest heavily in R&D and commercialization efforts for REVTORPYK and other pipeline candidates, backed by $642.7 million in cash, cash equivalents, and short-term investments.
Celcuity Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Celcuity Inc. (Nasdaq: CELC) announced its third-quarter 2026 financial results, highlighting the commercial launch of REVTORPYK™ (gedatolisib) for HR+/HER2- PIK3CA wild-type advanced breast cancer. The company reported a net loss of $73.3 million for the quarter but noted strong early adoption and broad payor coverage for REVTORPYK. Celcuity also provided updates on its clinical pipeline, including positive Phase 3 data for PIK3CA mutant breast cancer and ongoing trials for first-line breast cancer and metastatic castration-resistant prostate cancer.
Celcuity To Participate in Upcoming Investor Conferences
Celcuity Inc. announced that its CEO and Co-founder, Brian Sullivan, will present and hold one-on-one investor meetings at three upcoming investor conferences in November 2026: Guggenheim’s 3rd Annual Healthcare Innovation Conference, the Stifel 2026 Healthcare Conference, and the Jefferies Global Healthcare Conference. The company, a commercial-stage biotechnology firm, specializes in developing targeted therapies for solid tumor indications. Live webcasts and replays of the presentations will be available.
Celcuity To Participate in Upcoming Investor Conferences
Celcuity Inc. (Nasdaq: CELC) announced that its CEO and Co-founder, Brian Sullivan, will present at three upcoming investor conferences in November 2026. He will participate in fireside chats at Guggenheim’s 3rd Annual Healthcare Innovation Conference, the Stifel 2026 Healthcare Conference, and the Jefferies Global Healthcare Conference. Live webcasts of these presentations will be available through provided weblinks and the company's investor relations website.
Celcuity (CELC), What Is Behind The Latest Attention?
Celcuity (CELC) is gaining attention due to positive clinical data for its lead drug candidate, gedatolisib, which showed promising results in breast and prostate cancers. Despite recent share price volatility, the company's valuation suggests it is significantly undervalued by analysts, trading at a steep discount to fair value estimates. However, the investment narrative is balanced by concerns over substantial losses and increased debt related to launch preparations, which could pressure future earnings if revenue growth doesn't meet expectations.
Celcuity Inc. (CELC) Seasonal returns chart
This article provides a seasonal returns chart for Celcuity Inc. (CELC), showing the average monthly price return from 2017 to 2026. It also notes the upcoming Q3 2026 earnings call for CELC on November 5, 2026. The stock was trading at $70.07, up 4.47%, as of 11:49:39 am GMT-5.
Trading the Move, Not the Narrative: (CELC) Edition
This article provides an AI-generated analysis of Celcuity Inc. (NASDAQ: CELC), highlighting strong near and mid-term sentiment but a weak long-term outlook. It presents three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also details support and resistance signals across multiple timeframes.
Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Call
Celcuity Inc. (Nasdaq: CELC) announced it will release its third-quarter 2026 financial results on Thursday, November 5, 2026, after market close. Management will host a webcast/teleconference at 4:30 p.m. Eastern Standard Time on the same day to discuss the results and provide a corporate update. The company is a commercial-stage biotechnology firm developing targeted therapies for solid tumor indications, with its first FDA-approved product being REVTORPYK™ (gedatolisib).
Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Call
Celcuity Inc. has announced it will release its third-quarter 2026 financial results after market close on Thursday, November 5, 2026. Management will host a webcast and teleconference on the same day at 4:30 p.m. Eastern Standard Time to discuss the results and provide a corporate update. The company is a commercial-stage biotechnology firm focused on developing targeted therapies for solid tumors.
Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Call
Celcuity Inc. (Nasdaq: CELC) announced it will release its third-quarter 2026 financial results after market close on Thursday, November 5, 2026. The company will host a webcast and teleconference the same day at 4:30 p.m. Eastern Standard Time to discuss the results and provide a corporate update. Celcuity is a commercial-stage biotechnology company focused on developing targeted therapies for solid tumor indications, with its first FDA-approved product being REVTORPYK™ (gedatolisib).
H.C. Wainwright Maintains Celcuity(CELC.US) With Buy Rating, Maintains Target Price $155
H.C. Wainwright has reaffirmed its Buy rating for Celcuity (CELC.US) and maintained its target price at $155. This indicates continued confidence from the analyst firm in the company's future performance and valuation.
Celcuity (CELC) Posts Fresh ESMO Data, Is The 60% Undervaluation Case Still Intact?
Celcuity (CELC) recently presented new data at ESMO 2026 from its Phase 3 VIKTORIA-1 breast cancer trial and a Phase 1b/2 prostate cancer study of gedatolisib, leading to renewed interest in the stock. Despite recent share price volatility, the company's most popular valuation narrative suggests a fair value of about $161 per share, significantly above its current trading price of $65.25. The bullish outlook is contingent on future regulatory decisions for gedatolisib and physician adoption amid competing PI3K targeted options.
Celcuity Trial Finds 21.5-Month Progression-Free Survival in Breast Cancer Subgroup
An updated phase 3 analysis of Celcuity Inc.'s VIKTORIA-1 trial revealed a median progression-free survival of 21.5 months with its three-drug regimen for breast cancer patients with PIK3CA-mutated disease and no liver metastases, significantly outperforming the 9.1 months seen with the control regimen. The results, presented at the European Society for Medical Oncology Congress, highlighted "consistent and significant clinical benefit" from the triplet therapy. The FDA had previously approved gedatolisib for a different breast cancer population in July, and Celcuity submitted an application for its use in the PIK3CA-mutant HR-positive, HER2-negative population in August.
Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026
Celcuity Inc. announced updated subgroup analyses from its Phase 3 VIKTORIA-1 study, showcasing gedatolisib's effectiveness in HR+/HER2- advanced breast cancer patients with PIK3CA mutations. The gedatolisib triplet regimen significantly improved median progression-free survival, especially in patients without liver metastases, and demonstrated higher objective response rates with lower discontinuation rates compared to alpelisib plus fulvestrant. These findings were presented at the European Society of Medical Oncology (ESMO) Congress 2026, highlighting gedatolisib as a promising treatment option.
Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026
Celcuity Inc. announced updated subgroup analyses from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 study, presented at the ESMO Congress 2026. The data show that gedatolisib regimens significantly improved median progression-free survival (PFS) and objective response rates (ORR) compared to alpelisib plus fulvestrant in HR+/HER2- advanced breast cancer patients. Notably, patients without liver metastases treated with the gedatolisib triplet achieved a median PFS of 21.5 months, indicating a substantial clinical benefit.
Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026
Celcuity Inc. announced updated subgroup analyses from the PIK3CA mutant cohort of its Phase 3 VIKTORIA-1 study, showing gedatolisib-based regimens significantly improved progression-free survival (PFS) and objective response rates (ORR) in HR+/HER2- advanced breast cancer patients. Specifically, the gedatolisib triplet demonstrated a median PFS of 21.5 months in patients without liver metastases, compared to 9.1 months for alpelisib plus fulvestrant, and superior duration of response with lower discontinuation rates due to adverse events. These findings were presented at the ESMO Congress 2026 and highlight the potential of gedatolisib as a differentiated therapy.
How Drug Launch Coverage Will Impact Celcuity Stock (CELC) Investors
Cantor Fitzgerald has initiated coverage on Celcuity following the launch of its breast cancer therapy, Revtorpyk, with a focus on its near-term commercial opportunity and potential expansion into PIK3CA mutant disease. This launch marks a shift for Celcuity from a clinical-stage company to one that must execute on commercialization while managing heavy R&D spending. Analyst forecasts predict significant revenue and earnings growth by 2029, contingent on successful Revtorpyk uptake and positive future trial outcomes.
Celcuity reports phase 1b prostate cancer trial results
Celcuity Inc. announced positive results from its Phase 1b/2 study of gedatolisib combined with darolutamide for metastatic castration-resistant prostate cancer. The study showed promising radiographic progression-free survival rates and PSA decreases across different dose levels, with a manageable safety profile. The company plans to advance to the Phase 2 portion of the study in the first half of 2027.
Celcuity Presents Updated Data from a Phase 1b/2 Study
Celcuity Inc. announced updated clinical results from a Phase 1b/2 study of gedatolisib combined with darolutamide for metastatic castration-resistant prostate cancer (mCRPC). The data, presented at the ESMO Congress 2026, showed promising median radiographic progression-free survival rates of 15.7 months for patients who received prior abiraterone and 9.1 months for those with prior enzalutamide. The company plans to initiate the randomized Phase 2 portion of the study in the first half of 2027 to further evaluate the combination in mCRPC patients.
Celcuity Inc. Estimates – NASDAQ:CELC
This page provides financial actuals and analyst estimates for Celcuity Inc. (NASDAQ: CELC), allowing users to explore reported financial data across income statements, balance sheets, cash flow statements, and valuation metrics. It enables comparison of actual results with average, high, and low estimates, and visualization of trends over time. The platform emphasizes the importance of personal research and disclaims investment advice.
Cantor Fitzgerald Initiates Celcuity(CELC.US) With Buy Rating, Announces Target Price $140
Cantor Fitzgerald has initiated coverage on Celcuity (CELC.US) with a Buy rating. The investment firm has set a target price of $140 for the company's stock.
Cantor Fitzgerald initiates Celcuity stock with overweight rating
Cantor Fitzgerald has initiated coverage on Celcuity Inc (NASDAQ:CELC) with an overweight rating and a $140 price target, highlighting the company's potential for multi-billion-dollar peak sales in the oncology sector. Celcuity recently launched Revtorpyk for HR+/HER2- breast cancer, with plans to expand its target population next year. The stock currently trades at $61.56, and analyst consensus remains bullish despite a recent 50% decline.
Cantor Fitzgerald initiates coverage of Celcuity with Overweight rating, $140 price target
Cantor Fitzgerald has initiated coverage of Celcuity (CELC) with an Overweight rating and a price target of $140. This price target suggests a 127.4% upside from the previous closing price. The bullish outlook is driven by the significant commercial potential of Celcuity's drug, gedatolisib, which is projected to achieve peak sales of $2.7 billion from its second-line indication and an additional $1.6 billion from first-line breast cancer treatment, along with encouraging Phase 3 trial data.
Celcuity stock price target raised to $145 by TD Cowen on uptake
TD Cowen has raised its price target for Celcuity Inc. (NASDAQ:CELC) to $145 from a previously undisclosed level, maintaining a Buy rating due to strong early uptake expectations for its drug Revtorpyk. Other analysts, including Guggenheim, H.C. Wainwright, Citizens, and JPMorgan, have also reiterated or initiated Buy/Overweight ratings with price targets ranging from $155 to $177, signaling confidence in the company's cancer treatment therapies and the upcoming launch of Revtorpyk. Despite the stock appearing overvalued at current levels according to InvestingPro, Celcuity maintains liquid assets exceeding short-term obligations with a market cap of $2.94 billion.
Citizens reiterates Celcuity stock rating on ESMO data presentation
Citizens has reiterated a Market Outperform rating on Celcuity Inc (NASDAQ:CELC) with a $177.00 price target, despite a recent 14% stock decline. The company is set to present updated Phase 3 results for its drug VIKTORIA-1 at ESMO 2026 and early data for mCRPC, with analysts seeing significant upside potential. Celcuity also recently disclosed Q2 financial results and pricing details for REVTORPYK, anticipating its commercial launch in late Q3 2026.
Celcuity (CELC) Slides As Fair Value Debate Builds, Is It Still 65% Undervalued?
Celcuity (CELC) has seen a significant stock slide recently, dropping 30% in the last month, yet a prevailing narrative suggests it is 65% undervalued with a fair value of $161.09. This valuation is based on the potential of its drug gedatolisib in the advanced breast cancer market. However, the bullish outlook depends on future FDA decisions and clinical data, highlighting key risks to this investment thesis.
Celcuity Inc. (CELC) options chain
This Yahoo Finance page provides options chain information for Celcuity Inc. (CELC). As of October 16, 2026, the stock closed at $56.58, down 6.17%. The options data, which is delayed by 15 minutes, currently shows no available calls or puts for the specified date.
how InvestingPro’s Fair Value flagged Celcuity’s 52% decline By Investing.com
InvestingPro's Fair Value analysis accurately flagged Celcuity (NASDAQ:CELC) as severely overvalued in May 2026 when it was trading at $138.23. Despite some positive developments, the stock subsequently plummeted 52% to $65.85 by October 2026, validating the initial warning. This case demonstrates how a multi-methodology intrinsic valuation approach can help investors avoid significant losses even when short-term catalysts might suggest otherwise.
Form 4 Celcuity LLC For: 11 October By Investing.com
This article provides a brief notice about a Form 4 filing for Celcuity LLC, pertaining to October 11. Form 4 filings are typically used to report changes in beneficial ownership of securities by company insiders. The article offers no further details on the content of the filing itself.
Form 4 Celcuity LLC For: 11 October By Investing.com
This article from Investing.com reports on a Form 4 filing for Celcuity LLC, dated October 11. Form 4 filings are legally required documents submitted to the SEC in the United States, used to disclose transactions by company insiders in their own company's stock. The article provides minimal detail beyond the filing's existence and date.
Precision Trading with Celcuity Inc. (CELC) Risk Zones
This article from Stock Traders Daily provides a detailed analysis of Celcuity Inc. (CELC), highlighting weak near and mid-term sentiment and a neutral long-term outlook with elevated downside risk. It presents three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for various holding periods. The analysis emphasizes risk management and offers entry/target/stop-loss zones for precision trading.
Does REVTORPYK Launch Change The Bull Case For Celcuity Stock?
Celcuity has launched commercial sales of REVTORPYK in the US for advanced breast cancer, shifting its focus from clinical development to commercial execution. This move places scrutiny on its sales, cost base, and patient uptake, directly addressing prior concerns about its pre-revenue status and significant operating losses. Analysts anticipate substantial revenue and earnings growth by 2029, contingent on successful market penetration and financial management.
Does REVTORPYK Launch Change The Bull Case For Celcuity Stock?
Celcuity has launched commercial sales of REVTORPYK in the US for advanced breast cancer patients, shifting its focus from drug development to commercial execution. This move places Celcuity's operational effectiveness, cost management, and patient adoption under close observation, as the company transitions from a loss-making clinical-stage biotech to a profitable oncology business. Analysts project significant revenue and earnings growth by 2029, implying a substantial increase in value if the commercial rollout is successful and market expectations are met.
Form 4 Celcuity LLC For: 10 October By Investing.com
This article reports on the filing of Form 4 by Celcuity LLC on October 10. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the beneficial ownership of a company's stock by an insider. The article provides no specific details about the contents of the Form 4 filing, only its existence and date.
Celcuity (CELC) Short Interest & Short Float | Updated Oct 2026
This article provides an updated overview of Celcuity (CELC) short interest and short float as of September 30, 2026. It details that 10.98 million shares, or 25.89% of the public float, were sold short, marking a 3.35% decrease from the previous report. The piece also includes historical short interest data, a short interest ratio, and an explanation of key short interest metrics and their implications.
Celcuity (CELC) Is Down 17.3% After REVTORPYK US Launch And sNDA Filing News Event
Celcuity Inc. has launched REVTORPYK in the US for certain breast cancer patients and submitted an sNDA to broaden its use. This commercialization effort, along with the appointment of a new finance executive to the board, is critical for the company to manage cash burn and leverage as it transitions from a development-stage firm to a commercial one. The success of REVTORPYK's uptake by physicians will be key to offsetting ongoing losses and financial commitments.
Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026
Celcuity Inc. announced multiple presentations at the European Society for Medical Oncology (ESMO) Congress 2026, including a late-breaking rapid oral presentation and three poster presentations. These presentations will feature data from clinical trials of gedatolisib for HR+/HER2- advanced breast cancer and metastatic castration-resistant prostate cancer. The company's first FDA-approved product, REVTORPYK (gedatolisib), is highlighted, along with ongoing clinical trials.
Form 3 Celcuity Inc. For: Oct 01 Filed by: GRYSKA DAVID W
This article reports on a Form 3 filing by David W. Gryska for Celcuity Inc. The filing indicates Gryska's initial statement of beneficial ownership of securities as a Director, with the event date being October 1, 2026. The document details the reporting person's address, their relationship to the issuer, and confirms the filing is for one reporting person.
Celcuity to present gedatolisib trial data at ESMO congress
Celcuity Inc. will present clinical trial data for its product gedatolisib at the European Society for Medical Oncology Congress 2026 in Madrid. The presentations will include late-breaking rapid oral and poster sessions covering data from trials in advanced breast cancer and metastatic castration-resistant prostate cancer. Gedatolisib is an FDA-approved pan-PI3K and mTORC1/2 inhibitor for specific breast cancer patients.